The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020
https://doi.org/10.58838/2075-1230-2023-101-2-14-19
Abstract
The objective: to study the epidemiology and incidence of XDR tuberculosis given the updated definition.
Subjects and Methods. The results of replies to the specialized inquiry by the Russian Ministry of Health about results of microbiological diagnostics and MTB drug susceptibility tests were studied. To assess the incidence of pre-extensive drug resistance, general population data were used, and for extensive drug resistance, data from 8 regions of Russia were used.
Results. The incidence of pre-extensive drug resistance was 39,1% [95% CI 38,4–39,8] among tuberculosis cases with rifampicin resistance including 26,8% in new cases [95% CI 25,8–27,9]; among all cases receiving treatment for whom DST results were available, it made 20,2%, including primary resistance in 9,7%. The incidence of XDR among cases with pre-extensive drug resistance was 3,0% [95% uncertainty interval 1,8–5,3] for all cases, including primary resistance in 1,6% [95% uncertainty interval 0,2–5,7].
Conclusion. Despite the low incidence of pre-extensive drug resistance, it is expected to increase primarily due to growing resistance to fluoroquinolones. Resistance to innovative drugs, in particular XDR, is not yet a serious problem.
About the Authors
S. A. Sterlikov
Russian Research Institute of Health, Russian Ministry of Health
Russian Federation
Russian Federation
Sergey A. Sterlikov - Doctor of Medical Sciences, Deputy Head of Federal Monitoring Center for Prevention of Tuberculosis Transmission and Program Monitoring in the Russian Federation
1, Dobrolyubova St., Moscow, 127254
Phone: +7 (925) 507-82-21
I. A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director
4, Dostoyevsky St., Moscow, 127473
Yu. V. Mikhaylova
Russian Research Institute of Health, Russian Ministry of Health
Russian Federation
Russian Federation
Yulia V. Mikhaylova - Doctor of Medical Sciences, Professor, Chief Researcher, Project Manager
1, Dobrolyubova St., Moscow, 127254
V. G. Kudrina
Russian Medical Academy of On-going Professional Education, Russian Ministry of Health
Russian Federation
Russian Federation
Valentina G. Kudrina - Doctor of Medical Sciences, Professor, Head of Department of Medical Statistics and Digital Health Care
V. V. Testov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Vadim V. Testov - Doctor of Medical Sciences, Deputy Director for Organizational and Methodological Activities
4, Dostoyevsky St., Moscow, 127473
References
1. Bogorodskaya E. M., Sterlikov S. A., Popov S. A. The problem of tuberculosis rates estimation. Problemy Tuberkuleza i Bolezni Legkikh, 2008, no. 7, pp. 8–14. (In Russ.)
2. Bykovchenko I., Prozherina Yu. Anti-microbial therapy achieves a new level. Remedium, 2017, no. 7, pp. 38–45. (In Russ.)
3. Otraslevye i ekonomicheskie pokazateli protivotuberkuleznoy raboty v 2018–2019 gg. Analiticheskiy obzor osnovnykh pokazateley i statisticheskiye materialy. [Sectoral and economic rates for TB control in 2018-2019. Analysis of main rates and statistic materials]. Moscow, RIO TSNIIOIZ Publ., 2020, 92 p. ISBN 978-5-94116-030-3.
4. Otraslevye i ekonomicheskie pokazateli protivotuberkuleznoy raboty v 2019–2020 gg. Analiticheskiy obzor osnovnykh pokazateley i statisticheskiye materialy. [Sectoral and economic rates for TB control in 2019–2020. Analysis of main rates and statistic materials]. Moscow, RIO TSNIIOIZ Publ., 2021, 63 p. ISBN 978-5-6044140-6-4.
5. Letter no. 17-10-11893 by the Russian Ministry of Health as of 22.09.2016. 4 p. (In Russ.)
6. Tuberkulez organov dykhaniya u vzroslykh. [Respiratory tuberculosis in adults]. ICD10 A15/A16. Revised in 2018. 61 p. (In Russ.)
7. Tuberkulez u vzroslykh. Klinicheskie rekomendatsii. [Tuberculosis in adults. Guidelines]. Approved in 2020. Adults. Valid till 2022. 79 p.
8. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. WHO/HTM/TB/2013.2:40. ISBN 9789241505345.
9. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. WHO, 2021, 33. ISBN 978-92-4-001866-2.
10. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, 2019, ISBN 978-92-4-155052-9.
Review
For citations:
Sterlikov S.A., Vasilyeva I.A., Mikhaylova Yu.V., Kudrina V.G., Testov V.V. The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020. Tuberculosis and Lung Diseases. 2023;101(2):14-19. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-2-14-19
Views:
1069
Email this article 